GLP-1 Microdosing and Binge Eating: What the Research Shows About Cravings, Reward, and Loss of Control
GLP-1 drugs quiet hunger. Binge eating is often not about hunger at all. What the small studies so far actually found, where the brain's reward system fits in, and the one way a low-dose protocol can make evenings harder.
3.5%
LIFETIME PREVALENCE OF BINGE EATING DISORDER IN US WOMEN, 2.0% IN MEN (HUDSON, BIOLOGICAL PSYCHIATRY 2007)
27
ADULTS IN THE ONLY PUBLISHED PLACEBO-CONTROLLED GLP-1 TRIAL IN BINGE EATING DISORDER (ALLISON 2023)
0
GLP-1 MEDICATIONS APPROVED FOR BINGE EATING DISORDER. LISDEXAMFETAMINE IS THE ONLY FDA-APPROVED DRUG
A 38-year-old nurse working twelve-hour shifts described her pattern plainly: nothing all day, then half a loaf of bread, a tub of ice cream, and whatever was in the freezer between 9 p.m. and midnight, standing at the counter. She was not hungry when it started. When she read that GLP-1 drugs "turn off food noise," she hoped a low dose might turn this off too.
Her hope is common, and it is not unreasonable. GLP-1 receptors sit in the parts of the brain that process food reward, and people on these drugs often report that cravings fade. But binge eating disorder is a psychiatric diagnosis with its own drivers, and the clinical evidence for GLP-1 drugs in binge eating is far smaller than the evidence for weight loss. There is also a specific way a low-dose protocol can make binges worse if meals get skipped.
This article covers how common binge eating is, what the small studies of liraglutide, dulaglutide, and semaglutide found, the brain research behind the idea, the restriction trap, and how to track eating behavior rather than only weight.
Key takeaways
- •Binge eating disorder is the most common eating disorder in US adults, with a lifetime prevalence of about 3.5 percent in women and 2.0 percent in men in the National Comorbidity Survey Replication.
- •Small pilot studies of liraglutide and dulaglutide, and a 2023 retrospective review of semaglutide in 48 adults, reported lower binge eating scores. The one placebo-controlled trial, 27 adults on liraglutide 3.0 mg, found no statistically significant difference in binge episodes.
- •No GLP-1 drug is approved for binge eating disorder. Lisdexamfetamine, approved by the FDA in January 2015, is the only approved medication.
- •Skipping meals because appetite is low is a known trigger for evening binges, so regular meals with protein matter more on a GLP-1 protocol, not less.
- •Cognitive behavioral therapy for eating disorders remains the first-line approach under NICE guideline NG69, and around half of people in CBT trials stop bingeing by the end of treatment.
What counts as binge eating disorder?
Binge eating disorder is defined in DSM-5 as recurrent episodes of eating an unusually large amount of food in a discrete period, usually within about two hours, with a sense of loss of control. The episodes must happen at least once a week for three months and cause marked distress. Unlike bulimia nervosa, binge eating disorder does not involve regular purging, fasting, or excessive exercise to compensate.
Binge eating disorder is more common than anorexia and bulimia combined. The National Comorbidity Survey Replication, published by Hudson and colleagues in 2007, interviewed more than 9,000 US adults and found lifetime rates of 3.5 percent in women and 2.0 percent in men. Binge eating disorder is also far more evenly split between sexes than other eating disorders, and it is strongly linked with obesity, depression, and type 2 diabetes. Episodes typically cluster in the evening and are often set off by stress, boredom, or a long stretch without food.
Lifetime prevalence of eating disorders in US adults, %
National Comorbidity Survey Replication. Hudson JI et al., Biological Psychiatry 2007. DSM-IV criteria.
- Women
- Men
Surveys using the looser DSM-5 criteria generally find similar or slightly higher binge eating disorder rates.
Why would a GLP-1 drug affect binge eating at all?
GLP-1 drugs may affect binge eating because GLP-1 receptors are found in the brain's reward circuitry, not only in the gut and pancreas. Receptors in the ventral tegmental area and nucleus accumbens help regulate dopamine signalling around food. Animal studies from Dickson and colleagues in 2012 showed that activating GLP-1 receptors in these areas reduced the drive to work for sugar rewards in rats.
Human studies point the same way. In a 2014 brain imaging study in the journal Diabetes, van Bloemendaal and colleagues found that exenatide reduced brain activity in reward regions when people with obesity viewed pictures of appetizing food. In a 12-week study published in 2017, Blundell and colleagues found semaglutide 1.0 mg reduced energy eaten at a buffet lunch by about 24 percent, cut reported cravings, and lowered the relative preference for high-fat foods. A 2021 study by Friedrichsen and colleagues found the 2.4 mg dose reduced buffet intake by about 35 percent. Our article on GLP-1 drugs and food noise covers the craving side in more depth.
Reduction in energy eaten at a buffet meal versus placebo, %
Blundell J et al., Diabetes Obes Metab 2017; Friedrichsen M et al., Diabetes Obes Metab 2021. Rounded.
These studies measured appetite in people with obesity, not people diagnosed with binge eating disorder. No equivalent data exist for low doses.
What have studies of GLP-1 drugs in binge eating found?
Studies of GLP-1 drugs in binge eating have been small and mostly uncontrolled, and they point toward a possible benefit without proving one. Four studies make up most of the published evidence. Two pilot studies, of liraglutide in 2015 and dulaglutide in 2020, found binge eating scores or episode counts fell more than in comparison groups. A 2023 retrospective review of 48 patient records by Richards and colleagues found larger reductions in Binge Eating Scale scores in people prescribed semaglutide than in those prescribed lisdexamfetamine.
The one randomized, placebo-controlled trial is less encouraging. Allison and colleagues gave 27 adults with binge eating disorder either liraglutide 3.0 mg or placebo for 17 weeks. Binge episodes fell in both groups, and the difference between them was not statistically significant, though the liraglutide group lost more weight. A trial that small can easily miss a real effect, and it can just as easily have found one by chance. Larger randomized trials of semaglutide and tirzepatide in binge eating disorder are registered, but results were not published at the time of writing.
| Study | Design | Finding |
|---|---|---|
| Robert et al., 2015 | Pilot, 44 non-diabetic adults with obesity, liraglutide vs diet alone, 12 weeks | Binge Eating Scale scores fell more in the liraglutide group |
| Da Porto et al., 2020 | Pilot, adults with type 2 diabetes and binge eating disorder, dulaglutide vs other glucose drugs | Fewer binge episodes and lower BES scores with dulaglutide |
| Allison et al., 2023 | Randomized, placebo-controlled pilot, 27 adults, liraglutide 3.0 mg, 17 weeks | Binge episodes fell in both arms; the difference versus placebo was not statistically significant |
| Richards et al., 2023 | Retrospective chart review, 48 adults, semaglutide vs lisdexamfetamine vs both | Larger BES reductions in the semaglutide groups; no randomization |
Can a low-dose protocol make binge eating worse?
A low-dose GLP-1 protocol can make binge eating worse if quiet daytime appetite turns into skipped meals. Long gaps without food are one of the best-established binge triggers. The dietary restraint research of Polivy and Herman, going back to the 1970s and 1980s, showed that people who rigidly restrict food are more likely to overeat once restraint breaks. By evening, blood sugar is lower, willpower is spent, and the brake that a small GLP-1 dose applies to appetite has less to push against.
The nurse from the introduction is a good example. On her first weeks of a low dose, she found it even easier to skip breakfast and lunch, and her evening episodes did not change. What helped was a rule she agreed with her clinician: three meals at set times, each with 25 to 30 grams of protein, whether hungry or not. Once daytime intake was steady, the dose seemed to do more at night. Structured regular eating is also the first step of CBT for binge eating, so the two approaches reinforce each other. Our guide to protein strategy on a microdose has meal targets.
Two eating patterns on a low-appetite day, kcal by time of day
Illustrative data. Total intake is similar; the timing is not.
- Breakfast
- Lunch
- Dinner
- After 9 p.m.
In the skipped-meals pattern, 1,400 kcal arrive after 9 p.m., the window where most binge episodes happen.
Who should be cautious about GLP-1 drugs and eating behavior?
People with a current or past restrictive eating disorder, such as anorexia nervosa or bulimia nervosa, should not start a GLP-1 drug without eating disorder specialist input. An appetite-suppressing medication can reinforce restriction, and eating disorder clinicians have described cases of GLP-1 misuse in people with restrictive disorders since semaglutide became widely available. Binge eating disorder alone is different, but the line between binge eating and bulimia can blur if compensatory behaviors such as vomiting, laxatives, or fasting creep in.
Mood matters too. Binge eating disorder frequently occurs alongside depression and anxiety, and appetite changes can affect mood in either direction. Our article on GLP-1 drugs and mental health reviews what the data show. Any new low mood, rising preoccupation with food or weight, or new compensatory behavior is a reason to pause and talk to the prescriber, not to push through.
Where does therapy fit in?
Cognitive behavioral therapy for eating disorders, known as CBT-E, is the first-line approach to binge eating disorder in most clinical guidelines. The UK's NICE guideline NG69 from 2017 recommends guided self-help based on CBT as a first step for adults, moving to group or individual CBT if that is not enough. Around half of people in CBT trials stop binge eating by the end of treatment, and those gains tend to hold at follow-up.
Therapy and medication address different parts of the problem. CBT works on regular eating, the thoughts that set off episodes, and the rules about food that feed the restrict-binge cycle. A GLP-1 drug, if it helps at all, most plausibly softens the physical pull of cravings. Weight loss is not the main goal of CBT for binge eating, and weight loss alone does not mean binge eating has stopped. Most clinicians who discuss GLP-1 drugs for people who binge describe them as a possible addition to therapy, not a substitute.
How do you track binge eating rather than just weight?
Binge eating is tracked with a weekly episode count and a validated questionnaire such as the Binge Eating Scale. The Binge Eating Scale, developed by Gormally and colleagues in 1982, has 16 items and is scored from 0 to 46. A score of 17 or below suggests minimal binge eating, 18 to 26 moderate, and 27 or above severe. Filling it in every two to four weeks takes five minutes and gives a number that can be shared with a clinician.
A food diary that records when episodes happen, what came before them, and how long it had been since the last meal is the most useful single tool. Patterns show up quickly: a skipped lunch, a hard shift, a particular room in the house. Tracking weight alongside behavior matters, because weight can fall while binges continue, and that combination deserves attention.
Illustrative Binge Eating Scale scores over 16 weeks
One person on a low-dose protocol with guided CBT self-help. Illustration only. Bands from Gormally 1982.
Illustrative weekly binge episodes from a food diary
Illustration only. Progress is rarely a straight line.
Weeks 6 and 9 went back up. A bad week is data, not failure.
What is the takeaway?
The takeaway is that GLP-1 drugs act on brain circuits involved in food reward, and early studies hint at lower binge eating scores, but the only controlled trial so far was small and inconclusive. A low dose is not a fix for binge eating disorder, and used carelessly it can deepen the daytime restriction that sets up evening binges. Regular meals, therapy built for eating disorders, and honest tracking of behavior as well as weight are where the evidence is strongest. The nurse still has hard nights after long shifts. She has fewer of them, and she now eats lunch.
"A quieter appetite at noon is not a reason to skip lunch. It is the best chance you get to eat it calmly."
Frequently asked questions
Do GLP-1 medications reduce binge eating?
Early research suggests GLP-1 medications may reduce binge eating scores, but the evidence is thin. Small pilot studies of liraglutide and dulaglutide and a 2023 retrospective review of semaglutide reported fewer binge episodes or lower Binge Eating Scale scores. The only placebo-controlled trial published so far, a 27-person study of liraglutide 3.0 mg, did not find a statistically significant difference in binge episodes versus placebo.
Is any GLP-1 drug approved for binge eating disorder?
No GLP-1 medication is approved for binge eating disorder. The only FDA-approved medication for moderate-to-severe binge eating disorder in adults is lisdexamfetamine, approved in January 2015. Semaglutide, tirzepatide, and liraglutide are approved for type 2 diabetes and for chronic weight management, and any use for binge eating is off-label.
How might GLP-1 medications affect cravings and reward?
GLP-1 receptors sit in brain regions that handle food reward, including the ventral tegmental area and nucleus accumbens. Brain imaging studies, such as van Bloemendaal and colleagues in 2014, found that the GLP-1 drug exenatide reduced responses to pictures of appetizing food. In a 2017 study by Blundell and colleagues, semaglutide reduced reported cravings and the preference for high-fat foods, alongside a roughly 24 percent drop in energy eaten at a buffet meal.
What is the difference between binge eating and overeating?
Binge eating means eating an unusually large amount of food in a discrete period, usually within about two hours, with a sense of loss of control. Binge eating disorder, as defined in DSM-5, requires episodes at least once a week for three months, marked distress, and no regular purging or other compensatory behavior. Overeating at a holiday meal without loss of control does not meet this definition.
Can a low-dose GLP-1 protocol make binge eating worse?
A low-dose GLP-1 protocol can backfire if quiet appetite leads to skipped meals during the day, because long periods of under-eating are a well-known trigger for evening binges. Keeping regular meals with adequate protein, even when hunger is low, lowers that risk. Anyone who notices binges increasing, or compensatory behaviors such as vomiting or laxative use, should stop and talk to their clinician promptly.
Should people with a history of anorexia or bulimia use GLP-1 medications?
People with a history of anorexia nervosa or bulimia nervosa need specialist assessment before any appetite-suppressing medication, including a GLP-1 drug. Suppressing appetite can reinforce restriction, and eating disorder clinicians have reported cases of GLP-1 misuse in people with restrictive disorders. A history of these conditions is a reason for eating disorder specialist input, not a detail to leave off an intake form.
What is the first-line approach to binge eating disorder?
Cognitive behavioral therapy focused on eating disorders is the first-line approach in most guidelines. The UK's NICE guideline NG69 from 2017 recommends guided self-help based on CBT as the first step for adults, followed by group or individual CBT if needed. Around half of people in CBT trials stop binge eating by the end of treatment, and medication is usually discussed as an addition rather than a replacement.
How can progress with binge eating be tracked?
The two most practical measures are a weekly count of binge episodes from a food diary and the Binge Eating Scale, a 16-item questionnaire scored from 0 to 46. A BES score of 17 or below suggests minimal binge eating, 18 to 26 moderate, and 27 or above severe. Tracking both every two to four weeks shows whether changes in weight are matched by changes in eating behavior.
Clinical references
- Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry. 2007;61(3):348-358.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.
- Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide: a pilot study. Obesity Research and Clinical Practice. 2015;9(3):301-304.
- Da Porto A, Casarsa V, Colussi G, et al. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):289-292.
- Allison KC, Chao AM, Bruzas MB, et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obesity Science and Practice. 2023;9(2):127-136.
- Richards J, Bang N, Ratliff EL, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obesity Pillars. 2023;7:100080.
- van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251.
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754-762.
- Dickson SL, Shirazi RH, Hansson C, et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. Journal of Neuroscience. 2012;32(14):4812-4820.
- McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-246.
- Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. Addictive Behaviors. 1982;7(1):47-55.
- National Institute for Health and Care Excellence. Eating disorders: recognition and treatment (NG69). 2017.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice, not dosing instruction, and not a substitute for the prescriber, therapist, or clinician responsible for your care. No GLP-1 medication is approved for binge eating disorder, and nothing here describes a treatment for binge eating disorder or any other eating disorder. The appetite studies described used full therapeutic doses in people with obesity. The eating-pattern, Binge Eating Scale, and episode charts are illustrations and do not describe any real individual or predict any outcome. GLP-1 microdosing is an off-label approach and should only be undertaken under a prescriber's supervision. If you are struggling with binge eating, purging, or restriction, contact a qualified eating disorder professional; in the US, the ANAD helpline and NEDA resources can help you find support.